Filing Details
- Accession Number:
- 0000875320-23-000035
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-15 16:16:04
- Reporting Period:
- 2023-11-13
- Accepted Time:
- 2023-11-15 16:16:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1735944 | Reshma Kewalramani | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-11-13 | 5,097 | $377.00 | 113,809 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.
Billionaire Hedge Funds
